Back to Report Store Home

Constrained Public Healthcare Budgets and the Pharmaceutical Industry - Featuring Expert Panel Views From Industry Survey, 2018

  • Published: Nov-2018
  • Report Code: GBI093CBR
  • Report Format: pdf

Description

Table of Contents

EXECUTIVE SUMMARY

INTRODUCTION

2.1 Global Healthcare Expenditure to Reach $9.17 Trillion by 2020

2.2 US Healthcare Expenditure Consistently Higher Than Other Major Markets

2.3 Factors Contributing to Constrained Healthcare Budgets

2.4 GBI Research Industry Survey: Most Important Factors Constraining Healthcare Budgets I

2.5 GBI Research Industry Survey: Therapy Areas Contributing to Constrained Healthcare Budgets I

2.6 How Do Constraining Healthcare Budgets Impact the Pharmaceutical Industry?

 

 

LANDSCAPE

3.1 Pharma in a Changing Environment I

3.2 Current Landscape in Key Mature Markets I

3.3 Current Landscape in Key Emerging Markets I

3.4 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in Europe

3.5 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the US

3.6 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the Asia-Pacific

MAIN POLICIES APPLIED IN KEY MARKETS

4.1 Main Pricing and Reimbursement Policies Applied in Key Markets II

4.2 Health Technology Assessment Overview

4.3 Heterogeneity in Health Technology Assessment ‘Value’

4.4 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Europe

4.5 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in US

4.6 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Asia-Pacific

4.7 Overview of Managed Entry Agreements (MEA)

4.8 GBI Research Industry Survey: Future of Managed Entry Agreements in Europe

4.9 GBI Research Industry Survey: Future of Managed Entry Agreements in the US

4.10 GBI Research Industry Survey: Future of Managed Entry Agreements in Asia-Pacific

4.11 Pros and Cons of Managed Entry Agreements

 IMPACT ON PHARMACEUTICAL INDUSTRY

5.1 GBI Research Industry Survey: Impact of Constrained Healthcare Budgets on the Pharmaceutical Industry

5.2 Negative impacts of Constrained Healthcare Budgets

5.3 Impact on R&D

5.4 Future R&D priorities

5.5 Perspective of the Industry on Future R&D Priorities

5.6 Positive Impacts of Constrained Healthcare Budgets

5.7 Impact of FDA reforms

 

RESPONSE OF PHARMA COMPANIES

6.1 GBI Research Industry Survey: Industry Response

6.2 Strategic Manoeuvres: Mergers and Acquisitions

6.3 Implementation of digital technology

6.4 R&D changes

6.5 Operational changes: Outsourcing

6.6 Payer engagement

6.7 Integrated Care – the Sixth Emerging Business Strategy?

CONCLUSION

BIBLIOGRAPHY

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$8985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards